Le Lézard
Classified in: Science and technology
Subject: PARTNERSHIPS

ITUS Extends its Collaboration with Virtua Healthcare System


LOS ANGELES, CA--(Marketwired - May 09, 2017) - ITUS Corporation ("ITUS") (NASDAQ: ITUS), a company using the power of the immune system to diagnose cancer, today announced that it has extended its collaboration with Virtua Healthcare System. Pursuant to the extension, Virtua will continue to provide patient samples for ITUS's ongoing cancer study through May of 2018.

Robert Berman, ITUS's President and Chief Executive Officer stated: "Virtua has been an invaluable partner in working with us on our study, and the samples they will provide over the next year will help us reach the critical mass that we need to achieve our next milestones."

Virtua is part of The Penn Medicine Cancer Program and is accredited by both the American College of Surgeons and by the National Accreditation Program for Breast Centers. Virtua provides a full range of clinical oncology social work services to meet the psychological needs of cancer patients and their families.

ITUS Corporation
ITUS funds, develops, acquires, and licenses emerging technologies in areas such as biotechnology. The Company is developing a platform called Cchektm, a series of non-invasive, blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy. Additional information is available at www.ITUScorp.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

ITUS Corporation: FOCUSED ON INNOVATIONtm


These press releases may also interest you

at 04:09
China and Kazakhstan have always supported each other and have always been partners in times of challenges, Chinese President Xi Jinping said in a signed article in the Kazakhstanskaya Pravda newspaper and Kazinform International News Agency on...

at 04:05
H.I.G. Capital ("H.I.G."), a leading global alternative investment firm with $64 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to acquire CGH Group S.A. ("CGH" or the "Company"), a...

at 03:55
The International Nut and Dried Fruit Council (INC), conducted an extensive study on Latin America's Gen Z dietary...

at 03:44
Truecaller, the leading global platform for verifying contacts and blocking unwanted communication, is publishing its interim report for January-June on Friday 19 July 2024 at 07.30 CET.  Alan Mamedi, CEO and Odd Bolin, CFO presents the report and...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:09
China and Kazakhstan have always supported each other and have always been partners in times of challenges, Chinese President Xi Jinping said in a signed article in the Kazakhstanskaya Pravda newspaper and Kazinform International News Agency on...



News published on and distributed by: